RANEXA*60CPR 500MG R.P. ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 58 | Hypertrophic cardiomyopathy | 1 |
58. Hypertrophic cardiomyopathy
Clinical trials : 126 / Drugs : 135 - (DrugBank : 42) / Drug target genes : 46 - Drug target pathways : 162
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-004507-20-IT (EUCTR) | 22/02/2012 | 08/03/2012 | SHMC | RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS | symptomatic hypertrophic cardiomyopathy (SHCM) MedDRA version: 14.1;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10007541 - Cardiac disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: RANEXA*60CPR 500MG R.P. INN or Proposed INN: RANOLAZINE Other descriptive name: NA Trade Name: RANEXA*60CPR 750MG R.P. INN or Proposed INN: RANOLAZINE Other descriptive name: NA Trade Name: RANEXA INN or Proposed INN: RANOLAZINE Other descriptive name: NA | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. | NULL | Not Recruiting | Female: yes Male: yes | 100 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Spain;Germany;Italy |